By using an adjuvant-induced rat model of arthritis, we previously reported that the treatment with an A2AAR agonist reduced the severity of clinical signs, decreased arthritis-associated pain, and increased the serum levels of the anti-inflammatory cytokine IL-10 [16]. This evidence concerns the gene IL10 and arthritic joint disease.